Review compares 68Ga-pentixafor and 18F-FDG PET/CT in a single CLL patient

This publication is a case report and review of literature focusing on the diagnostic utility of 68Ga-pentixafor PET/CT imaging compared with 18F-FDG PET/CT imaging. The scope is restricted to a single 60-year-old woman diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma. The primary outcome assessed was diagnostic performance in evaluating tumor burden and delineating disease extent. No secondary outcomes were reported in this source.

The main synthesized finding indicates that 68Ga-pentixafor PET/CT detected more lesions with significantly higher tracer uptake compared with 18F-FDG. The direction of the result suggests superior performance for 68Ga-pentixafor PET/CT in this specific instance. However, the effect size was not reported, and absolute numbers were not provided. No p-values or confidence intervals were available to quantify the statistical significance beyond the qualitative description of 'significantly higher' uptake.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. The study limitations are inherent to the single-patient design, which precludes generalization to broader populations. The authors do not explicitly note additional limitations beyond the case nature. Consequently, the practice relevance remains uncertain given the lack of comparative statistical rigor and safety data.